Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all
British Journal of Haematology · 2026-07 · 209 (1) · 391-392
DOI: 10.1111/bjh.70568 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 20.05.2026. Verfasst von Felicetto Ferrara. Beteiligte Einrichtung: Division of Hematology, Cardarelli Hospital, Naples, Italy. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Bridged Bicyclo Compounds, Heterocyclic, Sulfonamides, Azacitidine. Die Arbeit nennt 10 Literaturangaben.
Abstract (Originalsprache)
Commentary on: Delia et al. How unfitness criteria can make a difference in treating AML patients with hypomethylating agents and venetoclax. Br J Haematol 2026; 208: 340‐343 .
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology, Cardarelli Hospital, Naples, Italy.
Zitieren
APA
Ferrara, F. (2026). Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all. British Journal of Haematology, 209(1), 391-392. https://doi.org/10.1111/bjh.70568
Vancouver
Ferrara F. Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all. British Journal of Haematology. 2026;209(1):391-392. doi:10.1111/bjh.70568
BibTeX
@article{Ferrara2026,
author = {Ferrara, Felicetto},
title = {Azacitidine–venetoclax in unfit acute myeloid leukaemia: One size does not fit all},
journal = {British Journal of Haematology},
year = {2026},
volume = {209},
number = {1},
pages = {391--392},
doi = {10.1111/bjh.70568}
}
EUVIMED